title: Integrin alpha6beta4 promotes expression of autotaxin/ENPP2 autocrine motility factor in breast carcinoma cells.
abstract: In advanced breast carcinomas, the alpha6beta4 integrin is associated with a migratory and invasive phenotype. In our current study, we show that expression of the alpha6beta4 integrin in MDA-MB-435 breast carcinoma cells leads to increased expression of the autocrine motility factor autotaxin, as determined by Affymetrix gene chip, real-time quantitative RT-PCR and immunoblot analyses. We further demonstrate that increased autotaxin secretion from integrin alpha6beta4 expressing cells acts to enhance chemotaxis through its ability to convert lysophosphatidylcholine (LPC) to lysophosphatidic acid (LPA) and accounts for 80% of the motogenic activity of the conditioned medium. We determine that integrin alpha6beta4-dependent overexpression of autotaxin in MDA-MB-435 cells is mediated by NFAT1, but not NFAT5, through the use of siRNAs that specifically target autotaxin, integrin beta4, NFAT1 and NFAT5. Finally, we show by electrophoretic mobility shift assays that two consensus NFAT binding sites found in the autotaxin promoter strongly and specifically bind NFAT1 from integrin alpha6beta4 expressing cells. In summary, we find that the alpha6beta4 integrin potentiates autotaxin expression through the upregulation and activation of NFAT1. These observations highlight for the first time a mechanism by which NFAT transcription factors can facilitate an invasive and motile phenotype downstream of integrin alpha6beta4 signaling.
authors.affiliation: Department of Surgery and the Sealy Center for Cancer Cell Biology, University of Texas Medical Branch, 301 University Blvd, Galveston, TX 77555, USA.
authors.forename: Min
authors.initials: M
authors.lastname: Chen
authors.forename: Kathleen L
authors.initials: KL
authors.lastname: O'Connor
mesh_terms: D001943:Breast Neoplasms / Q000235:genetics*; D045744:Cell Line, Tumor; D002633:Chemotaxis; D004268:DNA-Binding Proteins / Q000378:metabolism; D005260:Female; D005786:Gene Expression Regulation; D005956:Glucose-6-Phosphate Isomerase / Q000235:genetics*; D006023:Glycoproteins / Q000235:genetics*; D006801:Humans; D039161:Integrin alpha6beta4 / Q000502:physiology*; D008246:Lysophospholipids / Q000378:metabolism; D009097:Multienzyme Complexes / Q000235:genetics*; D050778:NFATC Transcription Factors; D009687:Nuclear Proteins / Q000378:metabolism; D020411:Oligonucleotide Array Sequence Analysis; D010713:Phosphatidylcholines / Q000378:metabolism; D043264:Phosphodiesterase I; D010727:Phosphoric Diester Hydrolases; D011755:Pyrophosphatases; D014157:Transcription Factors / Q000378:metabolism; D000099189:Lysophospholipase D
chemical_list: D004268:DNA-Binding Proteins; D005956:Glucose-6-Phosphate Isomerase; D006023:Glycoproteins; D039161:Integrin alpha6beta4; D008246:Lysophospholipids; D009097:Multienzyme Complexes; D050778:NFATC Transcription Factors; D009687:Nuclear Proteins; D010713:Phosphatidylcholines; D043264:Phosphodiesterase I; D010727:Phosphoric Diester Hydrolases; D011755:Pyrophosphatases; D014157:Transcription Factors; D000099189:Lysophospholipase D; C118125:NFAT5 protein, human; C494006:NFATC2 protein, human; C032881:lysophosphatidic acid